About: American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Cell Transplant and Cellular Therapy Patients in the United States

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Cell Transplant and Cellular Therapy Patients in the United States Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Cell Transplant and Cellular Therapy Patients in the United States
Creator	Shigle, Terri Shaw, J Alexander, Maurice Alexander2, Maurice Culos, Katie Culos6, Katie Lynn, Terri Mahmoudjafari, Zahra Mahmoudjafari1, Zahra Pharmd, Colleen Pharmd, Julianna Pharmd, Katie Pharmd, Maurice Pharmd, Ryan Pharmd, Shigle Roddy, Julianna Roddy3, Julianna Shaw2, Ryan Shigle4, Terri Timlin, Colleen Timlin5, Colleen
Source	Elsevier; Medline; PMC; WHO
abstract	Abstract The coronavirus-19 (COVID-19) pandemic poses a significant risk to patients undergoing hematopoietic stem cell transplant or cellular therapy. The American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Steering Committee aims to provide pharmacy practice management recommendations for how to transition clinical hematopoietic stem cell transplant (HCT) or cellular therapy pharmacy services utilizing telemedicine capabilities in the inpatient and outpatient setting to maintain an equivalent level of clinical practice but minimizing viral spread in a high risk, immunocompromised population. Additionally, the Steering Committee offers clinical management recommendations for COVID-19 in HCT and cellular therapy patients based on the rapidly developing literature. As the therapeutic and supportive care interventions for COVID-19 increase, collaboration with clinical pharmacy providers is critical to ensure safe administration in HCT patients. Attention to drug-drug interactions (DDI) and toxicity, particularly QTc prolongation, warrants close cardiac monitoring and potential cessation of concomitant QTc prolonging agents. Expanded indications for hydroxychloroquine and tocilizumab have already shown potential stress to usual supply chain. Detailed prescribing algorithms, decision pathways and specific patient population stock may be necessary. The COVID-19 pandemic has challenged every member of the healthcare team and we must continue to remain vigilant in providing pharmacy clinical services to one of the most high-risk patient populations and remain committed to providing compassionate and safe care for patients receiving HCT and cellular therapies.
has issue date	2020-04-17(xsd:dateTime)
bibo:doi	10.1016/j.bbmt.2020.04.005
bibo:pmid	32305359
has license	els-covid
sha1sum (hex)	63dc434f3fc78955b22f123292b7016ca9c665cb
schema:url	https://doi.org/10.1016/j.bbmt.2020.04.005
resource representing a document's title	American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Cell Transplant and Cellular Therapy Patients in the United States
has PubMed Central identifier	PMC7162779
has PubMed identifier	32305359
schema:publication	Biol Blood Marrow Transplant
resource representing a document's body	covid:63dc434f3fc78955b22f123292b7016ca9c665cb#body_text
is schema:about of	named entity 'stock' named entity 'cellular therapy' named entity 'developing' named entity 'stress' named entity 'clinical pharmacy' named entity 'Clinical Management' named entity 'Hematopoietic' named entity 'Hematopoietic' named entity 'TOCILIZUMAB' named entity 'TO PROVIDE' named entity 'PATIENT POPULATION' named entity 'INCREASE' named entity 'ATTENTION' named entity 'INTERVENTIONS' named entity 'TRANSITION' named entity 'CRITICAL' named entity 'PANDEMIC' named entity 'CLINICAL PHARMACY' named entity 'HCT' named entity 'HOW' named entity 'CHAIN' named entity 'QTC PROLONGATION' named entity 'RECOMMENDATIONS' named entity 'POPULATION' named entity 'telemedicine' named entity 'DDI' named entity 'Attention' named entity 'hydroxychloroquine' named entity 'minimizing' named entity 'patients' named entity 'services' named entity 'immunocompromised' named entity 'warrants' named entity 'QTc prolongation' named entity 'Affiliations' named entity 'Cell' named entity 'Special Interest Group' named entity 'pharmacy' named entity 'supply chain' named entity 'pharmacy services' named entity 'United States' named entity 'Hematopoietic Cell' named entity 'COVID-19' named entity 'Pharmacy Practice' named entity 'Special Interest Group' named entity 'Cellular Therapy' named entity 'QTc' named entity 'monoclonal antibody' named entity 'remdesivir' named entity 'viral membrane' named entity 'Clinical pharmacy' named entity 'electrolyte disturbance' named entity 'lopinavir' named entity 'glycosylation' named entity 'policies and procedures' named entity 'long-term' named entity 'metabolic pathways' named entity 'toxicity' named entity 'hematopoietic stem cell transplant' named entity 'clinical management' named entity 'cellular therapy'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software